Back to results
US 2003/0153530 A1Published application
Compositions containing therapeutically active components having enhanced solubility
AssigneeAllergan Sales, Inc.
InventorsOrest Olejnik, Edward D.S. Kerslake
Life of this patent
Estimating the term…
Abstract
Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
Claims52
A composition comprising:
- a therapeutically active component in an amount effective to provide a desired therapeutic benefit to a patient to whom the composition is administered;
- a solubility enhancing component, other than a cyclodextrin, in an amount effective to increase the solubility of the therapeutically active component in the composition relative to the solubility of an identical therapeutically active component in a similar composition without the solubility enhancing component;
- an oxy-chloro component in an effective amount to at least aid in preserving the composition;
- and
- a liquid carrier component.
2 more elements
A composition comprising:
- a therapeutically active component selected from the group consisting of alpha-2-adrenergic agonists and mixtures thereof in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered;
- an anionic cellulose derivative in an amount effective to increase the solubility of the therapeutically active component;
- a chlorite component in an effective amount to at least aid in preserving the composition;
- and
- an aqueous liquid carrier component.
2 more elements
A composition comprising:
- a tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered;
- a solubility enhancing component in an amount effective to increase the solubility of the tartrate of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline;
- a chlorite component in an effective amount to at least aid in preserving the composition;
- and
- an aqueous liquid carrier component.
2 more elements
A composition comprising:
- a therapeutically active component in an amount effective to provide a desired therapeutic benefit to a patient to whom the composition is administered;
- an oxy-chloro component in an effective amount to at least aid in preserving the composition;
- and
- a liquid carrier component, wherein the composition is substantially free of cyclodextrins.
1 more element
Dependencies are inferred from the claim text.